References
- The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell72(6), 971–983 (1993).
- Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington’s disease. J. Neuropathol. Exp. Neurol.44(6), 559–577 (1985).
- Sathasivam K, Hobbs C, Turmaine M et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet.8, 813–822 (1999).
- Aziz NA, Swaab DF, Pijl H, Roos RA. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington’s disease: clinical consequences and therapeutic implications. Rev. Neurosci.18(3–4), 223–251 (2007).
- Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat. Med.13(11), 1359–1362 (2007).
- Stefani M, Dobson C. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med.81(11), 678–699 (2003).
- Sapp E, Kegel KB, Aronin N et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol.60(2), 161–172 (2001).
- Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington’s disease. Exp. Neurol.159(2), 362–376 (1999).
- Tai Y, Pavese N, Gerhard A et al. Microglial activation in presymptomatic Huntington’s disease gene carriers: a combined C-11-PK11195 and C-11-raclopride PET study. Neurology66(Suppl. 2), A134 (2006).
- Tai YF, Pavese N, Gerhard A et al. Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain130(Pt 7), 1759–1766 (2007).
- Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH. Activation of the IκB kinase complex and nuclear factor-κB contributes to mutant huntingtin neurotoxicity. J. Neurosci.24(37), 7999–8008 (2004).
- Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol.171(6), 1001–1012 (2005).
- Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet.37(5), 526–531 (2005).
- Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann. Neurol.53(3), 292–304 (2003).
- Dalrymple A, Wild EJ, Joubert R et al. Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res.6(7), 2833–2840 (2007).
- Wild EJ, Tabrizi SJ. Predict-HD and the future of therapeutic trials. Lancet Neurol.5(9), 724–725 (2006).
- Bjorkqvist M, Wild EJ, Thiele J et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J. Exp. Med.205(8), 1869–1877 (2008).
- Wild EJ, Tabrizi SJ. Biomarkers for Huntington’s disease. Expert Opin. Med. Diagn.2(1), 47–62 (2008).
- Wolfgang JS. Microglia and Alzheimer’s disease pathogenesis. J. Neurosci. Res.77(1), 1–8 (2004).